SOVALDI is a groundbreaking hepatitis C (Hep C) treatment. Clinical studies have shown that SOVALDI combination therapy can be effective for people with genotypes 1, 2, 3, and 4.
See below for information on the results achieved by patients in clinical studies:
Halaven is an anti-cancer ("antineoplastic"or "cytotoxic") chemotherapy drug. This medication is classified as a "non-taxane microtubule inhibitor". (For more detail, see How Halaven Works below)
SOVALDI combination therapy cure rates in clinical studies
The table below includes the percentages of patients, in SOVALDI clinical studies, who were cured of the Hep C virus. Cure means the Hep C virus is not detected in the blood when measured 3 months after treatment is completed.
Clinical study details
Genotype 1 (GT1) and Genotype 4 (GT4):
In a clinical study of 327 patients with Hep C genotypes 1, 4, 5, and 6 without prior Hep C treatment taking SOVALDI + ribavirin + peginterferon alfa for a treatment duration of 12 weeks, the cure rate was 90% (295 out of 327 patients studied). The cure rate was 89% (261 out of 292 patients studied) for GT1 and 96% (27 out of 28 patients studied) for GT4.
Genotype 2 (GT2) and Genotype 3 (GT3):
In a clinical study of patients with Hep C genotypes 2 and 3 with and without prior Hep C treatment taking SOVALDI + ribavirin, the cure rate for patients with GT2 was 93% (68 out of 73 patients studied) and the cure rate for patients with GT3 was 84% (210 out of 250 patients studied).
Other Hep C clinical studies in GT2 and GT3 patients with and without prior Hep C treatment: